Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 4interventionalRules rewrite

Phase 4: testing Ropivacaine 0.5% Injectable Solution for Hip Osteoarthritis

The goal of this clinical trial is to evaluate whether different types of regional anesthesia can improve pain control and functional recovery after total hip arthroplasty in adult patients undergoing elective hip replacement surgery. The main questions it aims to answer are: Does the PENG block reduce opioid use in the first 48 hours after surgery more effectively than the combined L-ESPB + S-ESPB technique?

Official registry: https://clinicaltrials.gov/study/NCT07180979 · Poznan University of Medical Sciences · enrollment listed as 90

What this phase means

Phase 4: the treatment is already approved. This study asks new questions — longer-term effects, other diseases, or how it compares in everyday care.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Ropivacaine 0.5% Injectable Solution, Ropivacaine 0.2% Injectable Solution, or Ropivacaine 0.2% Injectable Solution. The registry lists allocation as randomized. The goal of this clinical trial is to evaluate whether different types of regional anesthesia can improve pain control and functional recovery after total hip arthroplasty in adult patients undergoing elective hip replacement surgery.

They plan to enroll about 90 people at Poznan. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

Comparison of Pericapsular Nerve Group (PENG) Block Versus Lumbar Erector Spinae Plane Block (L-ESPB) Combined With Sacral ESPB (S-ESPB) for Analgesia in Total Hip Arthroplasty (THA): A Randomized Clinical Trial

Interventions: Ropivacaine 0.5% Injectable Solution, Ropivacaine 0.2% Injectable Solution, Ropivacaine 0.2% Injectable Solution

Primary outcome (registry wording): Total opioid consumption

Who it is for (from inclusion criteria)

  • Ages 65 Years to 100 Years
  • ASA physical status I-III
  • Elective unilateral THA via posterior or lateral approach

Public study contact (from the registry)

Malgorzata Reysner, M.D. Ph.D.

+48 61 873 83 03

mreysner@ump.edu.pl

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseClermont-Ferrand
Not a traditional drug phase: Development of a screening algorithm designed to determine a "dysmobility" profile in patients with chronic illness. for Joint Osteoarthritis

Chronic illness is a public health issue and mobility loss is frequent in this population. Among its' multiple physical and psychological consequences, increased mortality and cardiovascular morbidity seem the main concern.

NCT04375280 · Official ClinicalTrials.gov record · University Hospital, Clermont-Ferrand

RecruitingNot a traditional drug phaseHelsinki
Not a traditional drug phase: Trapeziectomy for Thumb Osteoarthritis

A multi-center randomly assigned compared with a dummy treatment clinical trial which determines the how well it works of trapeziectomy in patients with persistent painful osteoarthritis at the base of the thumb. The primary outcome is patient reported evaluation of pain and function of the wrist and hand at 6 months after the randomization to treatment group.

NCT05127005 · Official ClinicalTrials.gov record · Tampere University Hospital

FAQ about this NCT record

Is NCT07180979 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07180979?

Phase 4. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07180979?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary